Laetitia E. Lamberts

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 341 citations · Full text

Breast Oncology, Oncology, Engineering +13

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Laetitia E. Lamberts, Maximillian Koch, Johannes S. de Jong et al. · Clinical Cancer Research · 2016 · 267 citations · Full text

Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9

Marcel Janse, Laetitia E. Lamberts, Lude Franke et al. · Hepatology · 2011 · 129 citations

Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad et al. · Molecular Cancer Therapeutics · 2016 · 107 citations

Drug Targeting, Antibody-conjugated Mmae, Medicine +15

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Laetitia E. Lamberts, C. Willemien Menke‐van der Houven van Oordt, Eva J. ter Weele et al. · Clinical Cancer Research · 2015 · 96 citations